Aether Pacific Pharmaceuticals has announced its expansion into the Australian market with the launch of its New Zealand-grown medicine.
The move comes after the company fulfilled regulatory and packaging requirements, paving the way for three strains of its cannabis products to be made accessible to Australia-based patients via prescription.
The dried cannabis flower strains have been cultivated to meet Australian regulations and adhere to EU-cGMP standards, with the THC content ranging from 17% to 25%.
Sourced from Aether’s 100%-owned medicinal cannabis growing division, Medical Kiwi, each strain will be sold in 10-gram jars.
Aether is collaborating with Melbourne-based pharmaceutical supplier Novachem, which will distribute the products across its pharmacy network.
The firm said it plans to leverage Novachem’s network to drive sales, while also collaborating with the group on potential educational initiatives to highlight the benefits of Aether’s medicinal cannabis suite.
The company’s entry into the Australian market is “an important step in our international expansion strategy” said chairman Aldo Miccio.
